MedTrace Logo

Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing

NCT07743086 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 886

Last updated 2026-08-03

No results posted yet for this study

Summary

The goal of this clinical trial is to:

* In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing
* In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients

Conditions

  • Solid Tumor Cancer

Interventions

DRUG

Standard of Care chemotherapy Following an Algorithm

Standard of care chemotherapy for solid tumor malignancies with dose adjustment according to the algorithm produced in phase 1 for Duffy-null positive patients

DRUG

Standard of Care chemotherapy following CTCAE criteria

Standard of care chemotherapy for solid tumor malignancies with dose modifications and delays according to the standard of care using CTCAE criteria.

Sponsors & Collaborators

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Vijendra Singh, M.D. · Barbara Ann Karmanos Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-04-30
Completion
2029-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743086 on ClinicalTrials.gov